Related Experiment Videos
Phenoxymethylpenicillin two or three times daily in bacterial upper respiratory tract infections: a blinded,
G Fyllingen1, A R Arnesen, J Rønnevig
1Medical Department, Apothekernes Laboratorium AS, Oslo, Norway.
Abstract:
In relation to compliance problems it was investigated whether phenoxymethylpenicillin dosed 2 or 3 times daily was equally effective in bacterial upper respiratory infections. In a randomized, controlled and single blind clinical trial, 131 patients with otitis media, sinusitis and tonsillitis were treated with phenoxymethylpenicillin. 71 received the daily dose twice a day and 60 patients received the daily dose 3 times a day. The dose was adjusted for diagnoses and age. Clinical cure was the endpoint for treatment success. In the 2-dosage group 78.6% had full effect of the treatment and 86.2% had full effect in the 3-dosage group. There was no statistically significant difference. In conclusion phenoxymethylpenicillin dosed 2 or 3 times daily seems to be equally effective in bacterial upper respiratory infection.
Insights
Phenoxymethylpenicillin for bacterial upper respiratory infections showed similar effectiveness when dosed twice or three times daily. This finding is relevant for improving patient compliance with antibiotic treatments.
Area of Science:
- Infectious Diseases
- Pharmacology
- Clinical Medicine
Background:
- Antibiotic resistance and patient compliance are critical challenges in treating bacterial infections.
- Optimizing dosing regimens for common antibiotics like phenoxymethylpenicillin can improve treatment outcomes.
- Upper respiratory tract infections (URTIs) are frequently treated with penicillins, necessitating efficient dosing strategies.
Purpose of the Study:
- To compare the clinical effectiveness of phenoxymethylpenicillin administered twice daily versus three times daily.
- To evaluate treatment success rates in patients with bacterial URTIs, including otitis media, sinusitis, and tonsillitis.
- To determine if a less frequent dosing schedule impacts therapeutic outcomes.
Main Methods:
- A randomized, controlled, single-blind clinical trial involving 131 patients diagnosed with bacterial URTIs.
- Patients were assigned to receive phenoxymethylpenicillin either twice daily (71 patients) or three times daily (60 patients).
- Dosing was adjusted based on patient age and specific diagnosis, with clinical cure as the primary endpoint.
Main Results:
- Clinical cure was achieved in 78.6% of patients in the twice-daily dosing group.
- A clinical cure rate of 86.2% was observed in the thrice-daily dosing group.
- No statistically significant difference in treatment effectiveness was found between the two dosing frequencies.
Conclusions:
- Phenoxymethylpenicillin demonstrates comparable efficacy in treating bacterial upper respiratory infections regardless of whether it is administered twice or three times daily.
- The findings suggest that a twice-daily dosing regimen may be a viable alternative, potentially improving patient compliance.
- Further research could explore long-term outcomes and cost-effectiveness of different dosing schedules for phenoxymethylpenicillin.